Coherus Oncology (CHRS) vs Cardiol Therapeutics (CRDL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Coherus Oncology (CHRS) over the past year, gaining 24.5% versus a loss of 40.9%. Over five years, CRDL leads with a -66.4% price change compared with -94.1% for CHRS. Cardiol Therapeutics is the larger company by market cap ($160.4 million vs $156.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | CRDL |
|---|---|---|
| Share price | $1.01 | $1.32 |
| Market cap | $156.05M | $160.40M |
| 1-day change | -1.94% | +0.76% |
| YTD return | -28.87% | +38.36% |
| 1-year return | -40.94% | +24.53% |
| 5-year return | -94.06% | -66.41% |
| EPS (TTM) | $-1.25 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $2.34 |
| 52-week low | $1.01 | $0.88 |
| Distance from 52-week high | -61.39% | -43.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +667.33% | +533.33% |
| Average volume | 1.14M | 1.39M |
| Shares outstanding | 154.50M | 121.51M |
| Employees | 144 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed CHRS by 65.5 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CHRS vs CRDL FAQ
Which is bigger, Coherus Oncology or Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $160.40M compared with $156.05M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or CRDL?
CRDL returned +24.53% over the past 12 months, compared with -40.94% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Cardiol Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.